Abstract:
OBJECTIVE:The aim of this study was to compare the efficacy and tolerability of quetiapine and divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorders. METHOD:Patients were included in this post hoc analysis if they scored > or = 14 on the Positive and Negative Syndrome Scale (PANSS) Excited Component (EC) and > or = 4 on at least one of the PANSS EC items, had a current diagnosis of bipolar I disorder, manic or mixed episode, and had a lifetime and/or current diagnosis of a disruptive behavioral disorder (DBD) [conduct disorder (CD) or oppositional defiant disorder (ODD)]. Thirty-three (92%) of the 36 subjects with bipolar disorder and DBD met the PANSS EC inclusion criteria. These thirty-three adolescents were randomized to quetiapine (400-600 mg/day) or divalproex (serum level 80-120 microg/mL) for 28 days in this double-blinded study. The primary efficacy measure was change in PANSS Excited Component (EC) score over the study period and at each time point. RESULTS:Repeated measures analysis of variance (ANOVA) demonstrated statistically significant within-treatment-group effects for divalproex (baseline = 20.6, end point = 13.3, p < 0.0001) and quetiapine (baseline = 18.8, end point = 10.8, p < 0.0001) for the PANSS EC. There were no statistically significant treatment group differences in PANSS EC changes from baseline to end point scores (p = 0.7, d = 0.14). Mixed regression analyses (comparison of slopes, DAY*TREATMENT) revealed that there was no significant difference in the rate of improvement in the PANSS EC scores between the two treatment groups [F(1,31) = 0.78, p = 0.39, d = 0.28]. CONCLUSIONS:Quetiapine and divalproex showed similar efficacy for the treatment of impulsivity and reactive aggression related to co-occurring bipolar and disruptive behavior disorders in adolescents. Quetiapine and divalproex are both useful as monotherapy for the treatment of impulsivity and reactive aggression in adolescents with bipolar and disruptive behavior disorders. Placebo-controlled studies are necessary.
journal_name
J Child Adolesc Psychopharmacoljournal_title
Journal of child and adolescent psychopharmacologyauthors
Barzman DH,DelBello MP,Adler CM,Stanford KE,Strakowski SMdoi
10.1089/cap.2006.16.665subject
Has Abstractpub_date
2006-12-01 00:00:00pages
665-70issue
6eissn
1044-5463issn
1557-8992journal_volume
16pub_type
杂志文章,随机对照试验abstract:OBJECTIVE:The purpose of this article was to systematically review the literature on stimulant and atomoxetine combination therapy, in particular: 1) Characteristics of patients with attention-deficit/hyperactivity disorder (ADHD) given combination therapy, 2) treatment strategies used, 3) efficacy and effectiveness, a...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,评审
doi:10.1089/cap.2012.0093
更新日期:2013-04-01 00:00:00
abstract:BACKGROUND:Still little is known about neuropsychological differences between boys and girls with attention-deficit/hyperactivity disorder (ADHD) and whether there are sex-specific differences in the modulation of attentional performance by methylphenidate (MPH). METHOD:In this study, 27 males and 27 females between 8...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1089/cap.2009.0060
更新日期:2010-06-01 00:00:00
abstract:OBJECTIVE:Although recent studies and meta-analyses confirm the efficacy of antidepressants in the acute phase of treatment for adolescent depression, there are few data available to allow assessment of the value of continued use of antidepressants in depressed adolescents after acute response. This study examines the ...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1089/cap.2008.0001
更新日期:2008-08-01 00:00:00
abstract::This single case reports an open trial of lamotrigine in the treatment of self-injurious behavior (SIB) and epilepsy in an 18-year-old female diagnosed with generalized seizure disorder, stereotypic movement disorder, and compulsive SIB in the context of profound mental retardation. Animal models of SIB suggest that t...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.1996.6.273
更新日期:1996-01-01 00:00:00
abstract:OBJECTIVE:Irritability is both a normal developmental phenomenon and a common psychiatric symptom in children. In psychiatric nosology, a distinction is made between chronic and episodic irritability. This study examines the validity of this distinction. METHODS:A sample of 776 youths received Diagnostic and Statistic...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2006.16.456
更新日期:2006-08-01 00:00:00
abstract:OBJECTIVE:The purpose of this study was to investigate the side effect risks from using one or more psychiatric medications (including antipsychotics, antidepressants, α-2 agonists, benzodiazepines, mood stabilizers, and stimulants) among a national cohort of children and adolescents. METHODS:A questionnaire survey wa...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2013.0036
更新日期:2014-03-01 00:00:00
abstract::Bipolar Disorders (BD) are often comorbid with disruptive behaviour disorders (DBDs) (oppositional-defiant disorder or conduct disorder), with negative implications on treatment strategy and outcome. The aim of this study was to assess the efficacy of quetiapine monotherapy in adolescents with BD comorbid with conduct...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2013.0063
更新日期:2013-10-01 00:00:00
abstract::The prevalence and treatment of behavioral and mental illnesses in the adolescent population are increasing, and many of the medications used are continued into adulthood. Increased vigilance is necessary when caring for this population to prevent side effects and drug interactions. In this short communication, we pre...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2005.15.693
更新日期:2005-08-01 00:00:00
abstract:OBJECTIVES:This study examines cardiovascular (CV) effects of guanfacine immediate-release (GUAN-IR), dexmethylphenidate extended-release (DMPH), and their combination (COMB) during acute and long-term treatment of youth with attention-deficit/hyperactivity disorder. METHODS:Two hundred seven participants aged 7-14 ye...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1089/cap.2015.0264
更新日期:2016-12-01 00:00:00
abstract:OBJECTIVE:The use of methylphenidate (MPH) in the treatment of attention-deficit/hyperactivity disorder (ADHD) is widely accepted; however, there is increased concern regarding its abuse potential. Few studies have examined the reinforcing effects of drugs in individuals receiving them for clinical purposes. This study...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1089/cap.2005.15.729
更新日期:2005-10-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to assess the efficacy and safety of the once-daily atomoxetine compared with placebo in pediatric patients with attention-deficit/hyperactivity disorder (ADHD) in Taiwan. METHOD:The study sample included 106 patients aged 6-16 years who met the Diagnostic and Statistical Manual of ...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1089/cap.2006.0091
更新日期:2007-08-01 00:00:00
abstract::Urinary catecholamine excretion was assessed in 15 boys with attention-deficit/hyperactivity disorder (ADHD) and 16 normal controls during a defined physical and mental task. Dihydroxyphenylalanine, dopamine, norepinephrine (NE), epinephrine (EPI), 3,4-dihydroxyphenylacetic acid, and 3,4-dihydroxyphenylglycol (DOPEG) ...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.1996.6.63
更新日期:1996-04-01 00:00:00
abstract::Self-report instruments commonly used to assess depression in adolescents have limited or unknown reliability and validity in this age group. We describe a new self-report scale, the Kutcher Adolescent Depression Scale (KADS), designed specifically to diagnose and assess the severity of adolescent depression. This rep...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/104454602760219153
更新日期:2002-07-01 00:00:00
abstract::A 10-year-old boy with a history of heart transplantation had a potentially life-threatening decrease in his cyclosporine (CSA) blood levels during administration of bupropion. Subsequently he had an increase in CSA levels while receiving methylphenidate. These occurrences represent potential drug-drug interactions in...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/104454601750284117
更新日期:2001-07-01 00:00:00
abstract:OBJECTIVE:The purpose of this study was to investigate clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials. METHOD:Thirty-six medication-naïve children ages 9-14 years diagnosed with attention-deficit/hyperactivity disorder (ADHD) were enrolled for 6 weeks in a crossover trial,...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1089/cap.2012.0085
更新日期:2013-11-01 00:00:00
abstract:OBJECTIVE:The purpose of this study was to evaluate the efficacy and safety of acute quetiapine monotherapy in adolescents with schizophrenia. METHODS:Patients ages 13-17 years with an American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) diagnosis ...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1089/cap.2011.0092
更新日期:2012-10-01 00:00:00
abstract::ABSTRACT Neuroleptic malignant syndrome (NMS) is a potentially fatal disorder associated with the use of neuroleptics. Clinical research on NMS to date has focused exclusively on adults, but increasing numbers of juvenile cases have been reported. Two cases of juvenile NMS treated by the authors are discussed to demon...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.1992.2.123
更新日期:1992-07-01 00:00:00
abstract::In clinical samples, juvenile bipolar disorder (JBPD) is frequently accompanied by co-morbid attention-deficit/hyperactivity disorder (ADHD). Clinical trials assessing combined psychopharmacological interventions in this population are scarce, and methylphenidate (MPH) may worsen manic symptoms. We conducted a randomi...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1089/cap.2009.0037
更新日期:2009-10-01 00:00:00
abstract::The diagnosis of bipolar spectrum disorders (BPSD) is difficult to evaluate in child and adolescent populations. The current study examines whether commonly used behavior checklists- the Child Behavior Checklist, Teacher Report Form, and the Youth Self-Report form-are clinically useful in making a differential diagnos...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1089/104454603322724869
更新日期:2003-01-01 00:00:00
abstract:OBJECTIVE:This study evaluates pediatric antidepressant prescribing practices of Nebraska clinicians. METHODS:Surveys were sent in July, 2005, to 1,521 prescribing clinicians throughout Nebraska to assess pediatric antidepressant use along with any practice changes following the U.S. Food and Drug Administration (FDA)...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2007.0049
更新日期:2008-02-01 00:00:00
abstract:OBJECTIVE:The purpose of this study was to evaluate the short- and long-term efficacy and safety of ziprasidone in children and adolescents with bipolar I disorder. METHODS:Subjects 10-17 years of age with a manic or mixed episode associated with bipolar I disorder participated in a 4 week, randomized, double-blind, p...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1089/cap.2012.0029
更新日期:2013-10-01 00:00:00
abstract:: Objective: To examine the role of Guanfacine Extended Release (GXR) in the management of behavioral disturbances in patients with Prader-Willi Syndrome (PWS). Methods: Twenty from a total of 27 individuals with genetically conf...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2018.0102
更新日期:2019-05-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD). METHOD:Eleven subjects (10 males) with TD (age 9-19 years, mean 13.36, standard deviation [SD] 3.33) who did not respond or wer...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1089/cap.2009.0035
更新日期:2009-12-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to examine the association between the CYP2D6 and CYP2C19 genotype-predicted combined phenotypes and short-term measures of psychotropic efficacy and toxicity. METHODS:A rater-blinded, retrospective genotype association design examined a cohort of hospitalized pediatric psychiatric ...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2008.0103
更新日期:2009-08-01 00:00:00
abstract:OBJECTIVES:To evaluate the 52-week safety/tolerability of oral olanzapine for adolescents with schizophrenia or bipolar mania and compare effectiveness of a standard versus intense behavioral weight intervention in mitigating risk of weight gain. METHODS:Patients 13-17 years old with schizophrenia (Brief Psychiatric R...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1089/cap.2016.0010
更新日期:2016-12-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to summarize results of a blinded review of potential suicidal events and analyses comparing incidence rates between paroxetine- and placebo-treated pediatric patients. METHOD:One thousand one hundred ninety-one (1191) children and adolescents received paroxetine (n = 642) or placeb...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,评审
doi:10.1089/cap.2006.16.77
更新日期:2006-02-01 00:00:00
abstract:BACKGROUND:The use of atypical antipsychotics is increasing in adolescent populations, but little is known about adherence with these treatments. This study examined postdischarge adherence of adolescents treated as inpatients with either olanzapine or risperidone. METHODS:Eighty-six (86) adolescent inpatients (43 per...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2005.15.901
更新日期:2005-12-01 00:00:00
abstract:OBJECTIVE:The glutamatergic prefrontal-striatal pathway has been implicated previously in the neurobiology of attention-deficit/hyperactivity disorder (ADHD). We used short echo proton magnetic resonance spectroscopy (1H-MRS) to examine glutamate in the prefrontal cortex, left striatum, and, as a control area, the occi...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2006.0008
更新日期:2007-02-01 00:00:00
abstract:BACKGROUND:Several studies have reported that patient ethnicity influences psychiatric diagnosis, although this has only been examined in adolescents in two prior studies. One study was based on an outpatient sample and the other was a retrospective study involving a relatively small sample of inpatients. We hypothesiz...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/104454601750143528
更新日期:2001-04-01 00:00:00
abstract::In the United States, the novel compound duloxetine has been approved for the treatment of major depressive disorder (MDD) and diabetic peripheral neuropathic pain in the adult population. There are currently no published data on the use of duloxetine in children and adolescents. This report describes the successful t...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2006.0042
更新日期:2007-02-01 00:00:00